|
Thursday, 12 March 2009 22:21 |
 Bristol-Myers Squibb Company (NYSE: BMY) has announced a global collaboration with Nissan Chemical Industries, Ltd. and Teijin Pharma Limited for the development and commercialization of NTC-801, a selective inhibitor of the acetylcholine-activated potassium ion channel (IKACh), currently in Phase I development in Japan, for the maintenance of normal sinus rhythm in patients with atrial fibrillation. |
|
Read more...
|
|
Thursday, 12 March 2009 21:09 |
|
InteKrin Therapeutics, Inc., a clinical stage biopharmaceutical company focused on diabetes, metabolism and obesity, announced it has completed enrollment of a 360 patient Phase 2b study of INT131, a novel, non-TZD selective modulator of PPAR gamma (SPPARM) for the treatment of Type 2 diabetes (T2DM). |
|
Read more...
|
|
Thursday, 12 March 2009 20:40 |
 Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) announced that a Phase III study of Rituxan® (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks. |
|
Read more...
|
|
Thursday, 12 March 2009 18:58 |
|
 The slashing of pharma’s in-house teams did not help contract sales provider PDII in 2008, with the company recording an operating loss of $36.4m (€28.5m), compared with a $14.3m deficit the previous year. |
|
Read more...
|
|
Thursday, 12 March 2009 18:48 |
|
German coating technology specialist Driam hopes its new Driaconti-T continuous tablet coating platform will win over manufacturers wishing to improve process efficiency in times of economic gloom. |
|
Read more...
|
|
Thursday, 12 March 2009 18:17 |
|
The FDA has found “significant objectionable conditions” at the Genzyme manufacturing facility that makes Lumizyme, creating another issue in the product’s approval process. |
|
Read more...
|
|
Wednesday, 11 March 2009 20:31 |
|
KV Pharmaceutical Company, a developer and marketer of branded and generic or non-branded prescription pharmaceutical products, has entered into a consent decree with the FDA regarding the company's drug manufacturing and distribution. |
|
Read more...
|
|
Wednesday, 11 March 2009 16:19 |
|
Mesa Laboratories, Inc. , a supplier of instruments and consumables for healthcare and manufacturing quality control applications, today announced the appointment of Dr. John J. Sullivan to the position of Chief Executive Officer (CEO), replacing Luke R. Schmieder, who has been the CEO since founding the company in 1982. |
|
Read more...
|
|
Wednesday, 11 March 2009 15:52 |
|
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced the publication of new data in the journal Molecular Therapy by Alnylam scientists and collaborators from the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT). |
|
Read more...
|
|
Wednesday, 11 March 2009 15:46 |
 Synosia Therapeutics today announced it has entered into a second agreement with Roche, adding a further promising molecule to Synosia's clinical pipeline. Under the new agreement, Synosia gains access to a new-generation 5-HT6 antagonist in phase I to be investigated for the treatment of cognitive disorders. |
|
Read more...
|
|
|
Thursday, 12 March 2009 21:36 |
|
The Healthcare and Science business of Thomson Reuters has released the white paper, "The Five Myths of Generic Competition," highlighting what originator pharmaceutical and biotech companies can do to improve their forecasting of the likely timing, source and intensity of competition from generic drugs. |
|
Read more...
|
|
Thursday, 12 March 2009 20:55 |
Dolomite, the world leader in microfluidic design and manufacture, today launched the Mitos Syringe Pump Extra Smooth (XS), a versatile pumping solution making complex and powerful microfluidic technologies possible. This innovative new pump system has been built on the success of the original Mitos Syringe Pump, but now incorporates a virtually pulse free flow rate.
|
|
Read more...
|
|
Thursday, 12 March 2009 20:23 |
Abbott announced the launch of VOYAGER™ NC Coronary Dilatation Catheter, a next-generation balloon dilatation catheter with high-pressure capability designed to optimize the treatment of patients with coronary artery disease (CAD) during angioplasty procedures. VOYAGER NC is now available in the United States, Europe and select countries in Asia and Latin America.
|
|
Read more...
|
|
Thursday, 12 March 2009 18:56 |
|
US President Barack Obama has nominated Kansas Governor Kathleen Sebelius as his candidate to serve as Secretary of the Department of Health and Human Services. |
|
Read more...
|
|
Thursday, 12 March 2009 18:45 |
|
At a time when many companies are downsizing, UK-based contract manufacturer Penn Pharmaceuticals has just announced a £12m (€13.5m) redevelopment project that could see the creation of 133 new jobs. |
|
Read more...
|
|
Thursday, 12 March 2009 18:14 |
|
Drug giants Pfizer and GSK may be among the first affected by last week’s US Supreme Court ruling upholding a product liability lawsuit against Wyeth despite FDA approved labelling. |
|
Read more...
|
|
Wednesday, 11 March 2009 16:54 |
|
Prescient Medical, a medical device company, has reached a crucial milestone by completing the enrollment of 30 patients in the first phase of its first-in-human clinical trial for the vProtect Luminal Shield, conducted at the Corbic Research Institute in Colombia. |
|
Read more...
|
|
Wednesday, 11 March 2009 15:56 |
 Family nurse practitioners need to be more aware of the commercial pressures they face as a result of their increased involvement in prescribing, according to a survey published in the March issue of the UK-based Journal of Advanced Nursing. |
|
Read more...
|
|
Wednesday, 11 March 2009 15:51 |
|
The Special Committee of the Board of Directors of Genentech, Inc. (NYSE:DNA) today urged Genentech shareholders to take no action at this time with respect to Roche's revised tender offer to acquire all of the outstanding shares of Genentech stock not owned by Roche at a price of $93 in cash per share. |
|
Read more...
|
|
Wednesday, 11 March 2009 15:44 |
|
Roche (SWX: RO, ROG;OTCQX: RHHBY) and Evotec (FSE: EVT; NASDAQ:EVTC) announced today that they have entered into an agreement for Phase II clinical development of EVT 101 in patients with treatment-resistant depression. The potential value of this transaction exceeds USD 300 million. |
|
Read more...
|
|
